Core Viewpoint - MiniMed has received FDA clearance for its next-generation insulin pump, MiniMed Flex, which is designed to be discreet and smartphone-controlled, enhancing the management of diabetes for users [1][3]. Product Features - MiniMed Flex is approximately half the size of the previous MiniMed 780G system and is designed to be screenless, making it more lifestyle-friendly [2][4]. - The pump utilizes the advanced SmartGuard adaptive algorithm with Meal Detection technology, which has shown clinical performance exceeding global Time in Range recommendations [2][5]. - It features a 300-unit insulin reservoir and is compatible with MiniMed's infusion set portfolio, including options that allow for up to 7 days of wear, significantly reducing the number of injections required [5][8]. Market Strategy - The launch will begin with a customer experience phase in spring 2026, followed by a broader commercial launch in summer 2026 [7]. - MiniMed has introduced the MiniMed Forward Program, allowing current users of the MiniMed 780G system to upgrade to the MiniMed Flex system at no additional cost [6][9]. Target Audience - The MiniMed Flex system is approved for individuals aged 7 and older with type 1 diabetes and for those 18 years and older with insulin-requiring type 2 diabetes [7]. Company Mission - MiniMed aims to improve the daily lives of people with diabetes through innovative technology that reduces the burden of diabetes management [3][11].